Products
| Product | Strength | Pack Size |
|---|---|---|
| Methylprednisolone Powder for Solution for Injection (Medason) | 500mg | 10 vials / box |
| Mycophenolate Mofetil Capsules | 250mg | 100 capsules / box |
| Mycophenolate Mofetil Tablets | 500mg | 50 tablets / box |
| Mycophenolic Acid Gastro-Resistant Tablets | 180mg | 120 tablets / box |
| Mycophenolic Acid Gastro-Resistant Tablets | 360mg | 120 tablets / box |
| Tacrolimus Capsules | 0.5mg | 50 capsules / box |
| Tacrolimus Capsules | 1mg | 100 capsules / box |
| Tacrolimus Capsules | 5mg | 50 capsules / box |
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.
Transplant Rejection
Organ transplant
Organ transplant is often the only treatment option for end-stage organ failure (e.g. liver, kidney and heart). However, transplant rejection is a major barrier. Currently, transplant recipients are required to receive lifelong immunosuppressive therapy to prevent transplant rejection.
Calcineurin inhibitors
Calcineurin inhibitors are used as monotherapy or in combinations with mycophenolic acid. Tacrolimus is recommended as the first-line option for rejection prophylaxis. Immediate-release and extended-release Tacrolimus are not interchangeable. Blood levels of calcineurin inhibitors should be monitored to allow appropriate dose adjustment.
Mycophenolic Acid
Mycophenolic Acid is used in combination with calcineurin inhibitors and corticosteroids for rejection prophylaxis. The most common side effects are nausea, vomiting, diarrhea and abdominal pain. Mycophenolic Acid is designed as gastro-resistant tablets to minimize the gastrointestinal side effects. Due to different pharmacokinetics, Mycophenolic Acid (as sodium salt) and Mycophenolate Mofetil (as ester prodrug) are not interchangeable. As Mycophenolic Acid may increases the risk of CMV infections, CMV prophylaxis should be considered.
Corticosteroids
Corticosteroids (e.g. Prednisolone, Methylprednisolone) are often used as a part of immunosuppression in the peri-operative and early post-transplant period. As long-term use of corticosteroids can lead to a variety of side effects, withdrawal should be considered after the early post-transplant period.
Organ transplant is often the only treatment option for end-stage organ failure (e.g. liver, kidney and heart). However, transplant rejection is a major barrier. Currently, transplant recipients are required to receive lifelong immunosuppressive therapy to prevent transplant rejection.
Calcineurin inhibitors
Calcineurin inhibitors are used as monotherapy or in combinations with mycophenolic acid. Tacrolimus is recommended as the first-line option for rejection prophylaxis. Immediate-release and extended-release Tacrolimus are not interchangeable. Blood levels of calcineurin inhibitors should be monitored to allow appropriate dose adjustment.
Mycophenolic Acid
Mycophenolic Acid is used in combination with calcineurin inhibitors and corticosteroids for rejection prophylaxis. The most common side effects are nausea, vomiting, diarrhea and abdominal pain. Mycophenolic Acid is designed as gastro-resistant tablets to minimize the gastrointestinal side effects. Due to different pharmacokinetics, Mycophenolic Acid (as sodium salt) and Mycophenolate Mofetil (as ester prodrug) are not interchangeable. As Mycophenolic Acid may increases the risk of CMV infections, CMV prophylaxis should be considered.
Corticosteroids
Corticosteroids (e.g. Prednisolone, Methylprednisolone) are often used as a part of immunosuppression in the peri-operative and early post-transplant period. As long-term use of corticosteroids can lead to a variety of side effects, withdrawal should be considered after the early post-transplant period.